|

Olutasidenib Clinical Trials

9 actively recruiting trials across 7 locations

▲ +1 trial since June 2026

Also known as: FT 2102, FT-2102, FT2102, IDH1-R132 Inhibitor FT-2102, Rezlidhia

Pipeline

Phase 1: 1Phase 2: 7Phase 4: 1

Top Sponsors

  • M.D. Anderson Cancer Center3
  • University of California, Davis1
  • Timothy Pardee1
  • Rigel Pharmaceuticals1
  • National Cancer Institute (NCI)1

Indications

  • Cancer9
  • Acute Myeloid Leukemia4
  • IDH1 Mutation2
  • Chronic Myelomonocytic Leukemia2
  • Myelodysplastic Syndrome2

Miami, Florida2 trials

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

University of Miami

Phase 2
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

University of Miami

Phase 2

Houston, Texas2 trials

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies

The University of Texas M. D. Anderson Cancer Center

Phase 2
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

MD Anderson Cancer Center

Phase 2

Birmingham, Alabama1 trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Duarte, California1 trial

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1

Orange, California1 trial

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

UCI Irvine Health

Phase 4

Sacramento, California1 trial

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

University of California Davis Comprehensive Cancer Center

Phase 2

Winston-Salem, North Carolina1 trial

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Atrium Health Wake Forest Baptist Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.